李艺瞳,李 莉

卵巢癌作为妇科恶性肿瘤中致死率较高的疾病，其治疗模式随着PARP多聚腺苷二磷酸核糖聚合酶抑制剂的应用发生显著变革。PARP抑制剂在卵巢癌患者维持治疗中可有效延长无进展生存期，但药物相关不良反应常导致患者治疗依从性下降，甚至中断治疗，影响临床获益。本文通过梳理奥拉帕利、尼拉帕利、鲁卡帕利等主流PARP抑制剂在卵巢癌维持治疗中的常见不良反应类型，结合临床研究数据与实践经验，从预防监测、分级干预、剂量调整、患者教育等维度提出系统性管理策略，并探讨当前不良反应管理的研究进展与未来方向，旨在为临床优化PARP抑制剂治疗方案、提升患者耐受性与生存质量提供参考。

PARP抑制剂；卵巢癌；维持治疗；不良反应；管理策略

[1] 冯果,李昱橦,王雅.术前FAR及NLR值与行腹腔镜卵巢癌根治术患者预后的关系分析[J].航空航天医学杂志,2025,36(10):1169-1171. [2] 张武香,李永川,冯海霞,等.芦荟大黄素调控circ_0008673/miR-502-5p轴对卵巢癌CAOV3细胞恶性生物学行为的影响及作用机制[J].中国老年学杂志,2025,45(19):4815-4821. [3] Shohdy S K,Kassem L,Gabriel B,et al.Homologous Recombination Deficiency Testing in Women With Ovarian Cancer:An Egyptian Multicentre Study.[J].BJOG:an international journal of obstetrics and gynaecology,2025, [4] B.A O,Laurence G,M.D O,et al.Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer(ROSELLA):An Open-label,Randomized,Controlled,Phase 3 Trial[J].Obstetrical&Gynecological Survey,2025,80(10):636-638. [5] Huang X,Gu X,Xing L,et al.Impact of neoadjuvant chemotherapy on the efficacy of sugammadex for neuromuscular block reversal in ovarian cancer patients:A prospective cohort study.[J].Journal of clinical anesthesia,2025,107 112012. [6] Nikeghbal P,Zamanian D,Burke D,et al.Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients[J].BMC Cancer,2025,25(1):1459-1459. [7] Yin X,Zhu X,Li N,et al.Fibrinolysis markers as predictive indicators of neoadjuvant chemotherapy efficacy in ovarian cancer patients.[J].Future oncology(London,England),2025,1-10. [8] Ribeiro F D A A,Ladeira Q T,Antunes G V M,et al.Molecular characterization of hereditary breast and ovarian cancer patients from a public precision medicine service in the Southeast Brazilian population[J].Scientific Reports,2025,15(1):33495-33495. [9] Liu X,Tao J.Knowledge,attitudes,and practices regarding chemotherapy-induced bone marrow suppression in ovarian cancer patients[J].World Journal of Surgical Oncology,2025,23(1):351-351. [10] 黄莹.协同护理干预联合康复指导对卵巢癌术后患者生存质量的影响[J].婚育与健康,2025,31(18):139-141. [11] Yuan H,Wang T,Yao H,et al.PARPis after PARPis in patients with recurrent epithelial ovarian cancer:a single institutional experience[J]. Journal of Ovarian Research,2025,18(1):206-206. [12] 马云芳,史昭,张慧,等.上皮性卵巢癌患者血清IGF-1､B7-H4､miR-362水平与ROMA指数和预后的关系[J].检验医学与临床,2025,22(18):2504-2509. [13] 王春雨,杜龙舟,周文生,等.卵巢癌术后患者血浆sEPCR､TF+MP､D-D表达与下肢DVT发生的关联性研究[J].河北医药,2025,47(09):1435-1439. [14] 姚晓红,邵才颖.荧光腹腔镜技术在卵巢癌患者手术治疗中的应用进展[J].浙江创伤外科,2025,30(09):1796-1800. [15] 鲍敏,刘梦月,雷娜,等.贝伐珠单抗治疗晚期卵巢癌的研究进展[J].药物评价研究,2025,48(10):3017-3026. [16] Lawler L C,Klennert M S,Cole C K,et al.Implementation of a stepwise process for somatic testing in patients with a new diagnosis of germline negative epithelial ovarian cancer.[J].Gynecologic oncology reports,2025,61 101935. [17] 梁芳.益气温阳活血方对中晚期卵巢癌化疗后增效减毒作用及抗凋亡机制[J].医学理论与实践,2025,38(18):3151-3154. [18] 张敏,张海燕,路中,等.颈部原发性神经内分泌癌合并卵巢肿瘤1例[J].肿瘤防治研究,2025,52(09):806-809. [19] 杨金丛,张欣萍,王正营.贝伐珠单抗联合TP化疗方案治疗晚期卵巢癌患者的效果[J].中国民康医学,2025,37(18):83-85+107. [20] 马焱,马尔克亚·卡马力拜克,徐梦莉,等.卵巢癌患者T淋巴细胞亚群变化及临床治疗的研究进展[J].新疆医学,2025, 55(09):1137-1141. [21] Bhima S,Pelluri R,Talluru S V,et al.Gemcitabine-Induced Bilateral Peripheral Edema with Hypersensitivity in a Patient with Ovarian Cancer[J].Indian Journal of Gynecologic Oncology,2025,23(4):121-121. [22] 杨春燕,张彩丽,张清华.卵巢癌肿瘤微环境中CD4+T淋巴细胞浸润水平与患者预后的关系[J].中国妇幼保健,2025, 40(19):3633-3637. [23] Shan Y,Cui Z,Yin G.A comment on"A multi-modal model integrating MRI habitat and clinicopathology to predict platinum sensitivity in patients with high-grade serous ovarian cancer:a diagnostic study".[J].International journal of surgery(London,England),2025, [24] 裴佳,赵栋.近红外荧光分子七甲基菁类染料在卵巢癌治疗中的应用与探索[J].中国计划生育和妇产科,2025,17(09):53-57+113. [25] 桂凌,程峰,王平.基于生物信息学分析构建卵巢癌预后分子诊断模型及临床价值分析[J].西部医学,2025,37(09):1390-1395. [26] 钱昱呈,乔金飞,李平,等.基于“态靶辨证”理论探讨构建卵巢癌辨治体系[J].吉林中医药,2025,45(09):1016-1020. [27] Qu H,Wei Q,Gu W,et al.Retrospective Study of Elderly Patients with Advanced Ovarian Cancer Who Did Not Undergo Surgery.[J]. The oncologist,2025, [28] Cánovas S M,Robles L J,Verdejo G J F,et al.PARP inhibitors-associated thrombosis in patients with ovarian cancer:a study of the Spanish Society of Medical Oncology(SEOM)thrombosis and cancer group.[J].Clinical&translational oncology:official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,2025,(prepublish):1-8. [29] Tsolakidis D,Chatzistamatiou K,Markopoulou E,et al.Utilization of Ligasure®Maryland Jaw Open Sealer/Divider with Nanocoating Improves Perioperative Parameters in Women with Advanced Ovarian Cancer Subjected to Cytoreductive Surgery[J].Journal of Clinical Medicine,2025,14(17):6293-6293. [30] Lu X,Zhu H.Outcomes and prognostic factors in patients with synchronous endometrial and ovarian cancer.[J].Archives of gynecology and obstetrics,2025,(prepublish):1-9.

点击下载PDF